Farmas USA

No se si hoy si mañana o la próxima semana, pero estamos en evolución pokemon.

CASC

Por cierto, que ya han cambiado la dirección.

CASC

Más del Bastardo del 20 de junio, 2 días antes de la dilución

What's gone wrong at Cascadian is too much dithering and not enough progress with the development of the company's HER2-targeted breast cancer drug ONT-380. The positive and well-deserved buzz generated about the drug at ASCO 2015 was squandered by a bad management team.

The clinical profile of ONT-380 in HER2+ breast cancer presented at ASCO 2016 remains promising. This drug looks active against HER2+ breast cancer, but the wasted year took a toll on the company's market valuation. Thankfully, Cascadian is under new management taking steps to move the development of ONT-380 forward.

Cascadian has about a year's worth of cash in the bank. More money is needed. Everyone knows this, which is not helping the stock price. A non-dilutive financing i.e. a Big Pharma/Big Biotech out-licensing deal for ONT-380 with a hefty upfront payment, would be nice. -> dilución hecha

The "new" Cascadian is doing a much better job communicating the ONT-380 story compared to the "old" Oncothyreon. If you haven't already, I recommend downloading the ONT-380 data slide deck from ASCO 2016. For more background, you can also go back and read the story I wrote about ONT-380 during ASCO 2015.

While there are reasons to be encouraged about the Cascadian reboot, significant questions about ONT-380 and its place in the treatment of HER2+ breast cancer remain unanswered. Is the positive effect of ONT-380 on brain metastases seen in the phase I studies real and will it be confirmed in the ongoing triplet combination phase II study?

The rate of Grade 3 diarrhea tied to ONT-380 crept up to 11% in the latest data update. That's still much lower than Puma's neratinib, which requires patients to take large amounts of Immodium to barely tolerate the drug. But what happens to this closely watched side effect when more patients are treated with ONT-380 in the larger phase II trial?

And finally, will the FDA allow Cascadian to file for ONT-380's approval based on results from the ongoing "HER2CLIMB" phase II study? (Assuming those ONT-380 results are positive, of course, which is, itself, a risk.)

Cascadian won't have the data needed to answer these questions for quite some time because the phase II study is still enrolling breast cancer patients. Patience is not a virtue of biotech investors.

https://www.thestreet.com/story/13610860/1/biotech-stock-mailbag-cascadian-therapeutics-global-blood-therapeutics-bad-favus.html

Parece interesante pero me llama la atención que su pipeline no tiene productos en fases avanzadas y que uno de sus productos estrella (el ONT-380) figure con licencia de Array biopharma. Quizás me pierdo algo ;) . Saludos

CASC

La molécula ONT-380 (antiguo ARRY-380) fue creada por Array y vendido a ONTY (actual CASC) que es el que lleva el desarrollo. Las condiciones del acuerdo fueron estas:

ONT-380 is an orally active, reversible and selective small-molecule HER2 inhibitor invented by Array and licensed to Oncothyreon for development, manufacturing and commercialization. The License Agreement replaces the prior Development and Collaboration Agreement under which Oncothyreon and Array were jointly developing ONT-380. As part of the License Agreement, Oncothyreon paid Array $20 million as an up-front fee. In addition, Oncothyreon will pay Array a significant portion of any payments received from sublicensing ONT-380 rights. If Oncothyreon is acquired within three years of the effective date of the current agreement, Array will be eligible for up to $280 million in commercial and other milestone payments. Array is also entitled to receive up to a double-digit royalty based on net sales of ONT-380.

ARRY/CASC

Gracias por la respuesta, mugiwara. La cual me ha llevado a repasar el impresionante pipeline de Array y los acuerdos que tienen con varias empresas para ceder productos y cobrar por ellos. Al menos por financiación no creo que vayan mal. Saludos

http://www.arraybiopharma.com/product-pipeline/

ARRY

GALE

Galena issues over 3.6M shares of stock to resolve outstanding issues

In a regulatory filing, Galena Biopharma (NASDAQ:GALE) discloses that, on July 6, it agreed to issue 3,125,000 shares of common stock to five parties to settle outstanding claims in a "certain matter."
In addition, it settled a securities class action lawsuit for $20M, $16.7M of which was paid by the company's insurance carriers and $2.3M in cash paid by the company on July 1. On July 6, it issued 480,053 shares of common stock pursuant to the court order.

http://seekingalpha.com/news/3192682-galena-issues-3_6m-shares-stock-resolve-outstanding-issues?source=email_rt_mc_readmore&app=1&uprof=44#/email_link

CASC

+8,57-10,48% en pre con 1940 acciones a 1,16 y 1,14

Edito: bajando. 685 más a 1,13.
Edito 2: se mantiene en 1,13. 10695 acciones lleva